Investor Update

Basel, 11 September 2006

Genentech receives complete response letter from FDA for Avastin in metastatic breast cancer

Dear Investor,
Please find attached a Genentech news release announcing that Genentech received a complete response letter from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Avastin with chemotherapy in first-line metastatic breast cancer.

Please do not hesitate to contact us if you have any further questions.